Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer

Immuneering Corporation announced that the US FDA has granted orphan drug designation to IMM-1-104 in the treatment of pancreatic cancer. IMM-1-104 is currently being evaluated in a Phase IIa clinical trial in patients with advanced solid tumors, including pancreatic cancer.